Recent perspective on CAR and Fcγ-CR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomes

[Display omitted] The chimeric antigen receptor T cell (CAR-T cell) immunotherapy currently represents a hot research trend and it is expected to revolutionize the field of cancer therapy. Promising outcomes have been achieved using CAR-T cell therapy for haematological malignancies. Despite encoura...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical pharmacology 2019-08, Vol.166, p.335-346
Main Authors: Marei, Hany E., Althani, Asma, Caceci, Thomas, Arriga, Roberto, Sconocchia, Tommaso, Ottaviani, Alessio, Lanzilli, Giulia, Roselli, Mario, Caratelli, Sara, Cenciarelli, Carlo, Sconocchia, Giuseppe
Format: Article
Language:English
Subjects:
Animals
CAR T cells
Fcγ-CR T cell
Hematological malignancies
Humans
Immunotherapy
Immunotherapy - methods
Immunotherapy - trends
Immunotherapy, Adoptive - methods
Immunotherapy, Adoptive - trends
Neoplasms - immunology
Neoplasms - therapy
Receptors, Chimeric Antigen - administration & dosage
Receptors, Chimeric Antigen - immunology
Receptors, IgG - administration & dosage
Receptors, IgG - immunology
Solid cancers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] The chimeric antigen receptor T cell (CAR-T cell) immunotherapy currently represents a hot research trend and it is expected to revolutionize the field of cancer therapy. Promising outcomes have been achieved using CAR-T cell therapy for haematological malignancies. Despite encouraging results, several challenges still pose eminent hurdles before being fully recognized. Directing CAR-T cells to target a single tumour associated antigen (TAA) as the case in haematological malignancies might be much simpler than targeting the extensive inhibitory microenvironments associated with solid tumours. This review focuses on the basic principles involved in development of CAR-T cells, emphasizing the differences between humoral IgG, T-cell receptors, CAR and Fcγ-CR constructs. It also highlights the complex inhibitory network that is usually associated with solid tumours, and tackles recent advances in the clinical studies that have provided great hope for the future use of CAR-T cell immunotherapy. While current Fcγ-CR T cell immunotherapy is in pre-clinical stage, is expected to provide a sound therapeutic approach to add to existing classical chemo- and radio-therapeutic modalities.
ISSN:0006-2952
1873-2968
DOI:10.1016/j.bcp.2019.06.002